Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.45 |
| ▸ | UGCG | Q16739 | 5/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793746 | 0.93 | SMO (0.53) | SMOTRPV1 | |
| SCHEMBL6792911 | 0.93 | SMO (0.47) | SMOLMNAHTTPOLBGAA | |
| SCHEMBL6795007 | 0.92 | SMO (0.48) | SMOLMNAHTTPOLBGAA | |
| SCHEMBL6788780 | 0.92 | RAB9A (0.42) | SMOLMNAHTTPOLBGAA | |
| SCHEMBL6791610 | 0.92 | SMO (0.42) | SMOLMNAHTTPOLBGAA | |
| SCHEMBL6799630 | 0.92 | SMO (0.42) | SMOLMNAHTTPOLBGAA | |
| SCHEMBL6793251 | 0.92 | SMO (0.42) | SMOTRPV1LMNAHTTPOLB | |
| SCHEMBL6793636 | 0.92 | SMO (0.42) | SMOTRPV1LMNAHTTPOLB | |
| SCHEMBL6800714 | 0.91 | SMO (0.42) | SMOTRPV1LMNAHTTPOLB | |
| SCHEMBL6788937 | 0.91 | SMO (0.42) | SMOTRPV1LMNAHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | SMO 2094/4885UGCG 903/4885TRPV1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.